Thus, in this study, we hypothesized that SMYD2 was overexpressed in lung cancer and identified SMAD3 as a direct target of SMYD2 via epigenetic regulation that promotes lung cancer metastasis. The gene discussed is SMAD3; the disease is lung carcinoma.